National Jewish Health
nationaljewish.orgTotal trials
109
Active
17
Phase 3
2
Total enrollment
155,389
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Omalizumab | — | — | — | — | 2 | ||
| Reslizumab | — | — | — | — | — | 1 | |
| Saracatinab | — | — | — | — | — | 1 | |
| Benralizumab | — | — | — | — | — | 1 | |
| Lipopolysaccharides | — | — | — | — | — | 1 | |
| mycobacteriophage | — | — | — | — | — | 1 |
Next readouts
- 2018-12
- 2019-07-25
- 2024-09-15
- 2026-09
- 2026-12-31
- 2028-04
Top conditions
- Cystic Fibrosis20
- Asthma16
- Atopic Dermatitis7
- Food Allergy4
- COPD4
- Idiopathic Pulmonary Fibrosis3
- Pulmonary Disease, Chronic Obstructive2
- Hypnotic Dependence Among Those With Insomnia2
Frequently asked questions about National Jewish Health
- How many clinical trials does National Jewish Health have on ClinicalTrials.gov?
- National Jewish Health is listed as the lead sponsor on 109 clinical trials in ClinicalTrials.gov, 17 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Jewish Health's trials are in Phase 3?
- 2 of National Jewish Health's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does National Jewish Health focus on?
- National Jewish Health's most-studied conditions on ClinicalTrials.gov are Cystic Fibrosis, Asthma, Atopic Dermatitis, Food Allergy, COPD.
- When are National Jewish Health's next clinical trial readouts?
- National Jewish Health has 6 upcoming primary-completion readouts tracked here; the soonest is “Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study”, expected around 2018-12.